<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699114</url>
  </required_header>
  <id_info>
    <org_study_id>PARIBU-020</org_study_id>
    <nct_id>NCT00699114</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain</brief_title>
  <official_title>Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this placebo controlled clinical trial is to evaluate the dose response
      relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in
      doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60
      mg on acute postoperative pain after surgical removal of impacted third molars.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acetaminophen (paracetamol) and related aspirin-like drugs have traditionally been used for
      pain control of minor to moderate postoperative pain. Gradually traditional non-steroidal
      anti-inflammatory drugs (NSAIDs) have become more popular as analgesics due to assumed
      superior therapeutic effects and aggressive marketing campaigns orchestrated by the
      pharmaceutical industry.

      Ibuprofen is a widely used analgesic both in non-prescription and prescription doses.

      A dose-response relationship for low ibuprofen doses is shown. Evidence of a progressing dose
      response relationship for moderate (i.e. 400 mg) to higher doses is scarce. A possible
      analgesic ceiling effect has been suggested for doses above 400 mg, although a correlation
      between given ibuprofen doses above 400 mg and patient serum levels is shown. However, it may
      be questioned if the plasma concentration of ibuprofen is an important determinator of
      analgesic drug efficacy. A higher dose is more likely to influence the duration of analgesic
      effect rather than the peak analgesic effect.

      There are few clinical trials investigating the dose-response relationship of increasing
      ibuprofen doses and paracetamol doses. To our knowledge no published study has investigated
      the dose-response relationship of ibuprofen and paracetamol in the same trial with a negative
      (i.e. placebo) and a positive (i.e. best standard analgesic treatment) control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum Pain Intensity Score(SPI)</measure>
    <time_frame>3 hour observation period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum Pain Intensity Difference Score (SPID)</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum Pain Intensity Score (SPI)</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum Pain Intensity Difference Score (SPID)</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Pain Intensity Difference Score (MAXPID)</measure>
    <time_frame>Unknown, calculated variable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Pain Intensity Difference Score</measure>
    <time_frame>Unknown, calculated variable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Occurrence of Adverse Effects</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Occurrence of Adverse Effects</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose ibuprofen 400 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose ibuprofen 600 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose ibuprofen 800 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 500 mg (acetaminophen) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose paracetamol 1000 mg (acetaminophen) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol 1000 mg + codeine 60 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose as powder in gelatine capsules, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg</intervention_name>
    <description>Ibuprofen 400 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <other_name>M01A E01 Ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg</intervention_name>
    <description>Ibuprofen 600 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Ibuprofen 600 mg</arm_group_label>
    <other_name>M01A E01 Ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 800 mg</intervention_name>
    <description>Ibuprofen 800 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Ibuprofen 800 mg</arm_group_label>
    <other_name>M01A E01 Ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (acetaminophen) 500 mg</intervention_name>
    <description>Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Paracetamol 500 mg</arm_group_label>
    <other_name>N02B E01 Paracetamol (acetaminophen)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (acetaminophen) 1000 mg</intervention_name>
    <description>Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Paracetamol 1000 mg</arm_group_label>
    <other_name>N02B E01 Paracetamol (acetaminophen)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (acetaminophen) 1000 mg + codeine 60 mg</intervention_name>
    <description>Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose</description>
    <arm_group_label>Paracetamol 1000 mg + codeine 60 mg</arm_group_label>
    <other_name>N02B E01 Paracetamol (acetaminophen) + R05D A04 codeine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes referred for surgical removal of impacted third molars, due to
             symptoms or after being advised to do so by their dentist.

          -  Persons of both sexes (ASA type I).

          -  Females who are not pregnant or plan conception.

          -  Persons who have not used analgesics for 3 days prior to the day of surgery.

          -  Persons without known active ulcus or gastrointestinal bleeding.

          -  Persons without any known hypersensitivity for NSAIDs.

          -  Persons under no other continuous drug treatment than contraceptives.

          -  Caucasian origin.

          -  Persons with at least moderate postoperative pain as defined by subjective score on a
             verbal rating scale after surgical removal of third molars.

        Exclusion Criteria:

          -  Patients with surgery time exceeding 60 minutes

          -  Peroperative complications such as profuse bleeding or perforation to the maxillary
             sinus requiring additional drug treatment during or after the surgical removal of the
             third molar.

          -  Postoperative complications such as extended bleeding, nausea and regurgitation during
             the observation period.

          -  Smoking before taking the test-drug or during the observation period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lasse A Skoglund, DDS, DSCi</last_name>
    <role>Study Chair</role>
    <affiliation>Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N-0317 Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Skjelbred, MD, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital, Kirkeveien 166, N-0407 Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaute Lyngstad, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N0317 Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>July 3, 2011</last_update_submitted>
  <last_update_submitted_qc>July 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Lasse A. Skoglund, DDS, DSci</name_title>
    <organization>University of Oslo</organization>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Molar</keyword>
  <keyword>Third</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Codeine</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Codeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

